期刊文献+

多发性骨髓瘤患者血清Cys-C水平变化及意义 被引量:4

下载PDF
导出
摘要 目的探讨多发性骨髓瘤(MM)患者血清胱抑素C(Cys-C)水平变化,并探讨其临床意义。方法采用全自动生化仪测定28例MM患者(MM组)的血清Cys-C、肌酐(Cr)、β2微球蛋白(β2-MG)。根据国际分期标准(ISS),28例MM患者中,Ⅰ期6例,Ⅱ期15例,Ⅲ期7例。另选20例健康体检者为对照组。结果 MM组血清Cys-C水平高于对照组,且Cys-C水平随其ISS分期的升高而升高(P均<0.05)。血清Cys-C水平与血β2-MG水平以及肾功能损伤程度呈正相关关系(r=0.956、0.867,P均<0.05)。结论 MM患者血清Cys-C水平上调,并与肾功能损害及肿瘤负荷有关;其可作为评价早期肾功能损害及肿瘤负荷的潜在指标。
作者 李和兰
出处 《山东医药》 CAS 2012年第30期59-60,共2页 Shandong Medical Journal
  • 相关文献

参考文献7

二级参考文献31

  • 1顾春瑜,郑磊,王前.血清胱抑素C在评价肾移植患者肾功能中的应用[J].国外医学(临床生物化学与检验学分册),2004,25(6):559-561. 被引量:64
  • 2李玉艳,杨振坤,李强.胱抑素C在临床中的应用进展[J].国际检验医学杂志,2006,27(9):812-813. 被引量:106
  • 3谢群芳,王叶舟,戴文森.血清胱抑素C清除值估测肾小球滤过率的临床评价[J].中国误诊学杂志,2007,7(9):1969-1970. 被引量:56
  • 4韩振武,赵然,邵树茂,韩迎春.血清胱抑素C用以评估肾小球滤过率的价值[J].中国误诊学杂志,2007,7(18):4222-4223. 被引量:69
  • 5[3]王海燕.肾脏病学.人民卫生出版社,2001:138.
  • 6Filer G, Prien F, Vollmer I, et al. Diagnostic sensitivity of serum cystatin for impaired glom erular filtration rate[J].Pediatr Nephrol, 1999,13 (6) : 501-505.
  • 7Randers E Erlandsen EJ. Serum cystatin C as an endogenous marker of the renal function; a review[J]. Clin Chem Lab Med,1999,37(4) :389-395.
  • 8Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer Ⅱ System[J]. Scand J Clin Lab Investing, 1999,59(1) :1-8.
  • 9Dickinson DP, Zhao Y, Thiesse M, et al. Direct mapping of seven genes encoding human type 2 cystatins to a single site located 20p11. 2[J]. Genomics,1994,24:172-175.
  • 10Ylinen EA, Ala-Houhala M, Harmoinen AP, et al. Cystatin C as a marker for glomerular filtration rate in pediatric patients[J]. Pediatr Nephrol, 1999,13(6): 506-509.

共引文献201

同被引文献40

  • 1韩振武,赵然,邵树茂,韩迎春.血清胱抑素C用以评估肾小球滤过率的价值[J].中国误诊学杂志,2007,7(18):4222-4223. 被引量:69
  • 2张之南,沈悌.血液病诊断及疗效标准[M].2版.北京:科学出版社,1999:10-16.
  • 3Heidtmann HH, Salge U, Abrahamson M, et al. Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines [J]. Clin Exp Metastasis, 1997,15 (4) : 368-381.
  • 4Kos J, Stabuc B, Cimeiman N, et al. Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression[ J ]. Clin Chem, 1998,44(12) : 2556-2557.
  • 5Terpos E, Katodritou E, Tsiftsakis E,et al. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration [J]. Haematologica,2009, 94(3):372-379.
  • 6de Vos J, Thykjaer T, Tarte K, et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonu- cleotide arrays [ J ]. Oncogene, 2002,21 (44) : 6848-6857.
  • 7Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma [J]. J Clin Oncol, 2005,23 (15): 3412-3420.
  • 8Van DE,Paiker JE, Katz IJ, et al. A comparison of cysta- tin C and creatinine-based predication equations for the estimation glomerular filtration rate in black South Afri- cans[J]. Nephrol Dial Transplant, 2011, 26 (9) : 1553- 1558.
  • 9Spector JT, Acien AN, Fadrowki J, et al. Associations blood Lead with estimated glomerular filtration rate using MDRD, CKD-EPI and serum cystainC-based equations[J]. Nephrol Dial Transplant ,2011,26(9) : 2786-2792.
  • 10Gashenko EA,Lebedeva VA, Brak IV, et al. Evaluation of serum procathepsin B,cystatin B and cystatin C as possi- ble biomarkers of ovarian cancer[J]. Int J CircumpolarHealth,2013,72(1) :309-313.

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部